Development of E1018 to treat P. falciparum malaria
E1018 treatment as novel PfcPheRS inhibitor for Malaria
SEE ALL PARTNER ORGANIZATIONS
Objectives
- Preclinical development of a novel mechanism-of-action antimalarial
In September 2014, Eisai entered into a joint research agreement with the Broad Institute (Cambridge, Massachusetts, United States, “Broad”) to develop a new antimalarial treatment. Eisai and Broad work together to jointly evaluate compounds screened from Broad’s library and identified E1018, a compound with the potential to be used in clinical trials. The goal of this research is to develop an oral medicine that will rapidly cure malaria, and by interrupting the transmission of plasmodium (the parasite that causes malaria), will prevent malaria reinfection.
Results and milestones
E1018 is a novel antimalarial drug (Phenylalanine tRNA synthetase (PheRS) inhibitor) currently being developed for the treatment of P. falciparum malaria. The Phase I clinical study is being conducted. Also, based on this project, we have a backup project to leverage a structure-based approach that has enabled identification of next generation inhibitors of a high-priority antimalarial target, PfcPheRS. The next-generation program is expected to retain the key advantages of that frontrunner program namely a novel MoA, multi-stage activity and predicted single-dose efficacy– with the potential for improvements in safety profile and cost of treatment.
Geographic Reach
- Global Commitment
Disease Area
- Infectious and Parasitic Disease
Target Population
- Men
- Women
- People with low incomes
- Children
Partner organizations
International Centre for Genetic Engineering and Biotechnology
Broad Institute
Geographic Reach
Global Commitment
Disease Area
Infectious and Parasitic Disease
- Malaria